Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $25.00 by Analysts at HC Wainwright

Sage Therapeutics (NASDAQ:SAGE) had its price objective reduced by stock analysts at HC Wainwright from $28.00 to $25.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 82.08% from the company’s previous close.

Several other research firms have also weighed in on SAGE. The Goldman Sachs Group reduced their target price on Sage Therapeutics from $28.00 to $19.00 and set a “neutral” rating for the company in a report on Friday. TD Cowen reduced their target price on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating for the company in a report on Thursday, April 18th. Morgan Stanley boosted their target price on Sage Therapeutics from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. Wedbush restated a “neutral” rating and issued a $24.00 target price on shares of Sage Therapeutics in a report on Wednesday, April 17th. Finally, Scotiabank dropped their price target on Sage Therapeutics from $34.00 to $19.00 and set a “sector outperform” rating on the stock in a research report on Thursday, April 18th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $37.72.

Sage Therapeutics Stock Performance

Shares of Sage Therapeutics stock traded up $0.15 during trading on Friday, hitting $13.73. 686,531 shares of the stock traded hands, compared to its average volume of 1,024,206. The stock has a market cap of $825.31 million, a P/E ratio of -1.53 and a beta of 0.86. Sage Therapeutics has a twelve month low of $10.92 and a twelve month high of $59.99. The company has a fifty day moving average price of $18.75 and a two-hundred day moving average price of $20.68.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.17). The firm had revenue of $7.90 million for the quarter, compared to analyst estimates of $5.26 million. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The firm’s quarterly revenue was up 139.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.46) earnings per share. On average, equities research analysts expect that Sage Therapeutics will post -6.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Sage Therapeutics

Several large investors have recently modified their holdings of the business. Teacher Retirement System of Texas increased its holdings in shares of Sage Therapeutics by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 15,278 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 698 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Sage Therapeutics by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 748 shares in the last quarter. CWM LLC increased its holdings in shares of Sage Therapeutics by 274.2% in the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 883 shares in the last quarter. Inspire Investing LLC increased its holdings in shares of Sage Therapeutics by 8.4% in the third quarter. Inspire Investing LLC now owns 15,049 shares of the biopharmaceutical company’s stock worth $310,000 after acquiring an additional 1,169 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Sage Therapeutics by 1.0% during the third quarter. Swiss National Bank now owns 118,200 shares of the biopharmaceutical company’s stock worth $2,433,000 after buying an additional 1,200 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.